{"schema_version":"1","generated_at":"2026-10-30T09:37:30.610Z","data_as_of":null,"url":"https://www.findmykol.com/kol/amy-weise","json_url":"https://www.findmykol.com/kol/amy-weise/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"amy-weise","name":"Amy Weise","credential":"DO","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Henry Ford Health","institution_url":"https://www.findmykol.com/institution/henry-ford-health","city":"Detroit","state":"MI","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1245448042","openalex":"A5017967471"},"summary":"Amy Weise is an Oncology physician affiliated with Henry Ford Health. OpenAlex indexes 137 publications with 2,016 citations (h-index 23); ClinicalTrials.gov lists 3 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":137,"cited_by_count":2016,"h_index":23,"latest_activity_year":2025,"source":"works"},"trials":{"count":3,"shown":3,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT01147016","title":"Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery","phase":"PHASE2","status":"TERMINATED","role":"Overall official","sponsor":"Barbara Ann Karmanos Cancer Institute","source_url":"https://clinicaltrials.gov/study/NCT01147016","trial_url":"https://www.findmykol.com/trial/NCT01147016"},{"nct":"NCT00861913","title":"Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery","phase":"PHASE2","status":"COMPLETED","role":"Overall official","sponsor":"National Cancer Institute (NCI)","source_url":"https://clinicaltrials.gov/study/NCT00861913","trial_url":"https://www.findmykol.com/trial/NCT00861913"},{"nct":"NCT00244933","title":"Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer","phase":"PHASE2","status":"COMPLETED","role":"Overall official","sponsor":"Barbara Ann Karmanos Cancer Institute","source_url":"https://clinicaltrials.gov/study/NCT00244933","trial_url":"https://www.findmykol.com/trial/NCT00244933"}],"source":"trials"},"payments":{"company_count":10,"program_years":{"first":2021,"last":null},"rows_total":12,"shown":3,"withheld":9,"rows":[{"payer":"Immunocore Limited","program_year":2024,"amount_usd":2300,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1245448042"},{"payer":"E.R. Squibb & Sons, L.L.C.","program_year":2024,"amount_usd":107.1,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1245448042"},{"payer":"Regeneron Pharmaceuticals, Inc.","program_year":2023,"amount_usd":1730.08,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1245448042"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1245448042","source":"payments"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Initial phase 1 dose escalation data for emiltatug ledadotin (Emi-Le), a novel B7-H4-directed dolasynthen antibody-drug conjugate.","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.3009","status":"verified"},{"title":"Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.23.02172","status":"verified"},{"title":"RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.23.02110","status":"verified"},{"title":"A phase 1 study of fianlimab (anti–LAG-3) in combination with cemiplimab (anti–PD-1) in patients with advanced HNSCC.","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2024.42.16_suppl.6038","status":"verified"},{"title":"Interim analysis of ABM-1310, a blood-brain barrier-penetrant BRAF inhibitor, in patients with <i>BRAF V600</i>-mutated solid tumors.","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2024.42.16_suppl.3107","status":"verified"}],"source":"works"},"contact":{"address_1":"4100 JOHN R","address_2":"KARMANOS CANCER CENTER","city":"Detroit","state":"MI","zip":"482012013","phone":"800-527-6266","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1245448042","source":"identity"},"similar":[{"name":"Philip Philip","slug":"philip-philip","institution":"Henry Ford Health","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/philip-philip","json_url":"https://www.findmykol.com/kol/philip-philip/profile.json"},{"name":"David Lanfear","slug":"david-lanfear","institution":"Henry Ford Health","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/david-lanfear","json_url":"https://www.findmykol.com/kol/david-lanfear/profile.json"},{"name":"Jessica Mellinger","slug":"jessica-mellinger","institution":"Henry Ford Health","specialty":"Gastroenterology","url":"https://www.findmykol.com/kol/jessica-mellinger","json_url":"https://www.findmykol.com/kol/jessica-mellinger/profile.json"},{"name":"Marvin Eng","slug":"marvin-eng","institution":"Henry Ford Health","specialty":"Interventional Cardiology","url":"https://www.findmykol.com/kol/marvin-eng","json_url":"https://www.findmykol.com/kol/marvin-eng/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":9,"publications":45}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2016-12-05","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}